Business, Free News Articles, Manufacturing

Innovative, Removable Mesh Sling Now Available for Exclusive Manufacture

LOS ANGELES, Calif. -- California firm, ProNova Partners, has been chosen to handle the sale of the patent and rights to an easily removable mesh sling based on the natural encapsulation around monofilament wires or its interconnected narrow and flat strips. This encapsulation allows its easy removability.

15-year-old Mergers and Acquisitions firm, Los Angeles based ProNova Partners, has announced their commission to facilitate the sale of a new, patented technology for the repair of urine and fecal incontinence. This breakthrough has the potential to take over almost the entire incontinence repair market valued at billions of dollars.

"We are proud that our work worldwide has now enabled us now to assist in bringing a life-transforming technology to the market for manufacture," stated Rick Carlson CEO and founder of ProNova Partners.

In the almost two decades of its existence, ProNova Partners has overseen the sale of more than 400 opportunities in divergent areas. "This broad experience in multiple areas of the marketplace has been critical to our work in the medical and tech arenas," Carlson continued.

The patented "sling" technology available for rights purchase comes in 3 versions, all covered by patents: a weaved version, a detachable flat version, and an inflatable version for adjustment of the sub-urethral support.

The developer, an MD and a prolific inventor who owns more than 20 issued US and tens of International Patents says, "The weaved version of the sling we developed looks similar to the currently available synthetic slings and can be made from the same materials. However, there are some significant differences: differing from all the other available slings ours are not knitted, they are weaved making them more flexible and thinner."

"We are proud to be offering the full rights and ownership of this technological breakthrough into the marketplace for manufacture," concluded Carlson. "The offering includes all patents and will improve quality of life immediately for hundreds of thousands of patients, and once released those numbers will grow to millions."

For detailed information go to: https://pronovapartners.com/engagement/patented-easily-removable-sub-urethral-sling-medical-device-company-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Safety and Security Solutions

New Technology, 28 Patents, for secure Iris ID. Utilized By the UN, US Army, Marine Corps, Navy, Homeland Security, and Many in Private Sector. Available for Investment or Purchase

LOS ANGELES, Calif. -- ProNova Partners, an L.A. based Mergers and Acquisitions firm, has been selected to oversee investment in or the sale of a patented, groundbreaking ID and security technology. This technology involves iris recognition including in the outdoors under bright sunlight, plus world-leading iris recognition tech secured by crypto wallet.

ProNova Partners, a fifteen-year-old Mergers and Acquisitions company, has announced their selection to oversee investment in or the full sale of a world-leading, patented, iris recognition technology.

This technology currently has clients such as the UN, the US Department of Homeland Security, the US Navy, US Marine Corps, the governments of India, the Philippines, Kenya, and numerous others in both the public and private sectors. Uses range from numerous physical security applications to blockchain and cryptocurrency applications.

"The producing company owns 28 patents on this tech," related Rick Carlson, CEO of ProNova Partners. "Its proprietary 'iris recognition in bright outdoors under sunlight' technology is coupled with innovative world-leading iris recognition to crypto wallet. This dramatically improves the security and convenience of digital assets on blockchain."

"This new technology will be usable and game-changing in both developed and emerging countries," announced Rick Carlson CEO and founder of ProNova Partners. "We are proud to be a part of bringing this to the world market."

The technology meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information-in short data stemming from virtually any source.

ProNova Partners has assisted expansion or sale of some 400 firms in its history, in multiple areas of the marketplace.

"We are very pleased to assist in the growth and expansion of this much needed and innovative technology," concluded Carlson. "This tech empowers users to safely and securely lock and unlock everything from bank and medical transactions to equipment and even clothing. It could well change the way everything is done, and to do so with 'no mistake security' for every user."

For detailed information go to: https://pronovapartners.com/engagement/patented-world-leading-iris-recognition-technology-firm-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles

New, Patented Device for Quick, Painless, Non-Invasive Elimination of Hemorrhoids Now Available with All Rights for Manufacture

LOS ANGELES, Calif. -- ProNova Partners, a seventeen-year-old California based Mergers and Acquisitions firm, has been commissioned to assist in the sale of all rights to manufacture and sell a patented, painless, non-invasive, device to eliminate hemorrhoids. Use of the device requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital.

This technology has yielded a painless, non-invasive, no anesthesia needed device to eliminate hemorrhoids in under 2 minutes. The procedure can be performed in any medical setting.

"Over half of adults suffer from this affliction at one time or another," stated Rick Carlson founder and CEO of ProNova Partners. "This Doctor developed device offers a fast, painless and permanent solution."

Carlson's firm has helped the expansion or sale of some 400 companies in a wide variety of market segments.

This latest commission for ProNova is designed to structure movement of the patent, sale, and manufacturing rights of a much-needed device to an outside company. The goal is quickly move the technology out and into the medical marketplace. The product, developed and currently sold on a limited basis in the US, was originated by a gastroenterologist. It is currently sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience is gastroenterologists.

"Huge numbers of patients now no longer need to use ineffective creams or receive painful, invasive surgery," concluded Carlson. "This device offers a permanent, painless solution."

For detailed information go to: https://pronovapartners.com/engagement/patented-medical-device-company-for-hemorrhoid-removal-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Manufacturing

End-to-end transport Solution for Medical therapies and Products Relying on Cold Chain: Secure, Traceable, Reusable

LOS ANGELES, Calif. -- Southern California based Mergers and Acquisitions firm ProNova Partners has been commissioned to facilitate investment in or the sale of a patented, groundbreaking packaging technology. The technology facilitates a secure, traceable, and reusable end-to-end transport solution for expensive medical therapies and products that rely on the cold chain.

17-year-old Mergers and Acquisitions firm, ProNova Partners, has announced their commission to facilitate the manufacture and sale of a patented, portable refrigerator and freezer that provides remote tracking, monitoring and Chain-of-Custody for therapeutics and vaccines.

It protects temperature sensitive medical therapeutics such as COVID-19 Vaccines and Biological and Cellular Therapies including controlled substances that are being distributed and need to be stored at remote, last mile locations. It can be used for Clinical Trials, Home Infusion, Compounding Pharmacies delivering to the home, Academic Research Laboratories and Consumer applications.

"This new technology will save lives in both developed and emerging countries," announced Rick Carlson CEO and founder of ProNova Partners. "We are proud to be a part of bringing this to the world market."

ProNova Partners has assisted expansion or sale of some 400 firms in its history, in multiple areas of the marketplace. "We are very gratified to be able to lend a hand in the movement of great technology such as this into the market."

The technology has resulted in the smallest, most portable "cold chain" system available, with the longest autonomy time between recharges (>96hrs). It has been built for durability and reliability by the best thermal engineers on the planet. Designed for both transport in an airline cabin or as air cargo freight, it is an all-in-one solution that provides security, real-time alerts, and traceability for temperature sensitive medical products. The system has controlled room temperature, plus refrigerated and frozen set points. It has dual heat and cool modes and is based on a military grade, micro refrigeration compressor.

"This system enables better health care delivery by making the cold chain possible in places where there is limited to no cold chain or electrical infrastructure," concluded Carlson. "By utilizing less than 2 W/Hr, it can easily be recharged with a small solar panel."

For detailed information go to: https://pronovapartners.com/engagement/medical-transport-solution-for-cold-chain-products-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Funding and Investment

AI Radiology and Emerging Medical Technology Venture Capital Investment Group Now Open to Outside Participation

LOS ANGELES, Calif. -- Seventeen-year-old ProNova Partners has been contracted to facilitate the expansion of an Artificial Intelligence Radiology Imaging and emerging Medical Technology Venture Capital Investment Group.

"This venture capital investment partnership was founded in 2018," announced Rick Carlson, CEO of ProNova Partners. "On behalf of their members, they find and invest in game changing, cutting edge, emerging companies specializing in Artificial Intelligence Radiology Imaging and other Medical Technologies."

"The group is owned and operated by three managing partners with broad ranging domain expertise," continued Carlson. "We are very pleased to work with such a qualified group. They are finding and investing at the early stages in firms at the razor's edge of Artificial Intelligence in medical technology." Carlson's company has assisted the expansion or sale of some 400 companies in a wide variety of market segments.

"The investment group has already seen high quality, sector specific deal flow, and boasts of a robust current portfolio of investments in leading edge technologies," concluded Carlson.

"The investment firm's distinguished Managing Partners' combined credentials span venture capital investment expertise. This includes domain expertise in radiology covering a broad range of aspects of radiology and MRI imaging, entrepreneurship, artificial intelligence, and other emerging medical technologies. Their combined knowledge and experience establish them as ideally suited to spearhead the formation of a selected group of physician and non-physician investors plus providing groundbreaking leadership in early stage company investments in the AI/Imaging/Radiology sector."

For detailed information go to: https://pronovapartners.com/engagement/ai-radiology-and-emerging-technology-firm-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Patent and Trademark

Life Saving Device for Major Heart Surgery Procedure Now Available for Exclusive Manufacture

LOS ANGELES, Calif. -- ProNova Partners, a Los Angeles based, 25-year-old Mergers and Acquisitions (M&A) firm has announced their commission to facilitate the sale of a new, patented device to lower mortality and other risks in specific, major heart surgery procedures.

The device lowers mortality, stroke risk and other risk factors in Transcatheter Aortic Valve Implantation (TAVI) or transcatheter aortic valve replacement (TAVR) procedures.

"We are very pleased that our past work, both nationally and internationally, has enabled us now to assist in bringing a life-saving device to the market for manufacture," announced Rick Carlson CEO and founder of ProNova Partners.

ProNova Partners has facilitated the sale of over 400 various opportunities in divergent areas. "This broad range of experience and exposure in multiple areas of the marketplace has been very helpful to our consultation work in the medical and tech arenas," Carlson stated.

The patented device available for rights purchase can simply be added to existent equipment to immediately improve patient outcomes. It was developed by a renowned M.D. and professor, a prolific inventor who owns more than 20 issued U.S. and tens of International Patents and a similar number of pending patents.

According to the developer "The vision of our Project (was) to significantly improve the safety of TAVI/TAVR. Integrating or adding-on an active double-filtering, emboli capturing, collecting and removal component to the TAVI/TAVR procedure is a breakthrough. With our approach, we are bringing a better solution than the currently used deflective anti-embolic devices for preventing cerebral embolic complications."

"We are proud and pleased to be a part of offering the full rights and ownership into the marketplace for manufacture," concluded Carlson. "It will both save lives and improve quality of life immediately for hundreds of thousands of patients and once released those numbers will grow to millions."

For detailed information go to: https://pronovapartners.com/engagement/medical-device-company-for-major-heart-surgery-for-sale/

Related link: https://www.pronovapartners.com/

This news story was published by the Neotrope® News Network - all rights reserved.